522 results on '"Schuler, M"'
Search Results
2. Medication literacy in patients with oral tumor therapy
3. Prognostic value of deep learning-derived body composition in advanced pancreatic cancer—a retrospective multicenter study
4. P2.28-02 Impact of the Covid-19 Pandemic on Lung Cancer Diagnosis in a German Comprehensive Cancer Center. Are we still paying the debt?
5. MA21.09 More Accurate Staging of Stage IV Lung Cancer Through EUS B of the Left Adrenal Gland
6. MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors
7. Invasives versus nicht-invasives mediastinales Lymphknoten-Staging bei neuroendokrinen Lungentumoren
8. Der prognostische Stellenwert des Thyroidalen-Transkriptionsfaktor 1 (TTF-1) für das Langzeitüberleben bei Patienten mit pulmonalen Karzinoiden
9. Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting
10. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer
11. First Clinical Experience with Gallium-68-OPS-202 PET for Imaging SCLC
12. Palliative care outpatients in a German comprehensive cancer center—identifying indicators for early and late referral
13. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma
14. Multimodal survival prediction in advanced pancreatic cancer using machine learning
15. Patient-reported outcome measures 3 and 6 months after pulmonary rehabilitation following COVID-19
16. EP04.02-007 First Comprehensive Lung Cancer Long-Term Survivorship Program- Competing Risks
17. Prognostic factors after pneumonectomy in lung cancer
18. EP16.03-004 Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C Inhibition
19. Präoperative Immun-Checkpoint-Inhibitor-Therapie bei Frühstadien des nicht-kleinzelligem Lungenkrebs: NEOpredict-Lung – eine randomisierte, multizentrische Phase-II-Studie
20. Präoperatives PET-SUVmax und Volumen-basierte PET Parameter des Primärtumors sind nicht prädiktiv für Upstaging des N-Stadiums im Frühstadium Lungenkrebs
21. EP04.02-005 First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival
22. EP16.04-002 Combining Patient-Derived Xenografts and Barcoding Technology to Evaluate Response to Targeted Therapies in ALK+NSCLC
23. MA06.08 Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC
24. 76P Second interim analysis of INFINITY: A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
25. EP04.01-016 First Comprehensive Lung Cancer Long-Term Survivorship Analysis - Late Toxicities and Overall Survival
26. P1.14-05 TROP2 Expression and SN38 Antitumor Activity in Malignant Pleural Mesothelioma Cells
27. LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
28. EP02.01-010 Preoperative PET-SUVmax and Volume Based PET Metrics of the Tumor Fail to Predict Nodal Upstaging in Early-Stage Lung Cancer
29. Preclinical assessment of molecularly targeted therapy on novel pleural effusion derived mesothelioma cell models
30. Influence of Nickel on the Properties of P91 Flux Cored Wire Weld Metal
31. POS1138 PERSISTENCY OF DEPRESSIVE SYMPTOMS AND PHYSICAL PERFORMANCE IN KNEE OSTEOARTHRITIS
32. 1 Jahr pneumologische Post-Covid-Rehabilitation (4/2020 – 4/2021): Unterscheiden sich die Ergebnisse der Patienten mit Post-COVID-Syndrom von jenen mit noch akuter bzw. fortwährend symptomatischer COVID-19?
33. Symptomverlauf 3 und 6 Monate nach stationärer pneumologischer Rehabilitation nach COVID-19
34. P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100
35. MA14.03 Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib
36. PARPACT – Paramedic Palliative Care Test
37. 1212P Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases
38. 922P Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
39. Maligne Hodentumoren
40. Grundlagen der systemischen Therapie
41. Maligne Hodentumoren
42. Grundlagen der systemischen Therapie
43. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
44. Pneumologische Rehabilitation bei Post-Covid-19-Patienten: Erfahrungen und Kurzzeitbehandlungsergebnisse
45. Obstruktive Schlafapnoe (OSA) bei Patienten in pneumologischer Rehabilitation nach COVID-19
46. Reduzierte Exazerbationsraten 3 Monate und 1 Jahr nach pneumologischer Rehabilitation bei Patienten mit nicht kontrolliertem Asthma – Sekundäranalyse der EPRA-RCT
47. Sozialmedizinischer Status von COPD Patienten 12 Monate nach stationärer Rehabilitation
48. PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis
49. P86.03 A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations
50. Integrated substation condition monitoring
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.